From gene editing to GMP: building scalable, immune-shielded iPSC-derived cell therapies

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

From gene editing to GMP: building scalable, immune-shielded iPSC-derived cell therapies

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

As cell therapies become more highly engineered, how do you maintain the balance between functionality, manufacturability, and cost? This webinar shares practical lessons from immune-shielded induced pluripotent stem cell (iPSC)-derived beta cell and γδ T cell programs, showing how early engineering decisions shape downstream manufacturing, quality control strategy, and clinical translation.

You will see functional data on immune evasion and cell killing performance, alongside approaches to GMP-aligned gene editing and whole-genome sequencing-based quality assessment.

Attend this webinar to:

Review in vitro functional and immune assay data on immune evasion and cell killing performance from immune-shielded iPSC-derived beta cell and γδ T cell programs.
Learn key considerations for implementing GMP-aligned gene editing, immune-shielding strategies, and CAR engineering in iPSC-derived products.
Understand how whole-genome sequencing and advanced genetic characterization support and strengthen robust quality control strategy and successful clinical translation of gene-edited cell therapies.
Take away practical guidance on assessing scalability and cost of goods early in development, including the questions to ask as allogeneic programs advance.

Register now to bring your questions to the live discussion and learn how to design engineered iPSC-derived therapies that remain manufacturable and cost-effective at scale.

Stephanie Sontag, PhD

Head of CAR T Cell Program at Evotec

Stephanie Sontag is Senior Research Scientist and Head of the CAR T Cell Program at Evotec International, where she leads the development of an iPSC-derived CAR γδ T cell platform for the treatment of solid tumors. Stephanie has over 10 years of research and development experience in the life sciences, spanning both academic and industry settings, with a focus on pluripotent stem cells and hematopoietic development, genome editing, and stem cell–derived cell therapies. She earned her PhD in Biomedical Engineering from RWTH Aachen University, where her research focused on modelling human dendritic cell development using genetically engineered iPSCs. Stephanie subsequently worked as a Research Scientist at Taconic Biosciences, developing and optimizing CRISPR/Cas genome-editing protocols for genetically engineered mouse models, followed by a postdoctoral position at the Helmholtz Institute for Biomedical Engineering, where she established qualitative and quantitative epigenetic profiling methods for blood cells.

Katrin Ridders, PhD

Principal Scientist, iPSC Cell Therapy at Evotec

Dr Katrin Ridders is Principle Scientist at Evotec International’s department for iPSC Cell Therapy, where she strategically leads programs on gene-engineered iPSC-derived cell replacement therapies targeting insulin-dependent diabetes and heart failure. She has over 15 years of experience directing multi-site international and interdisciplinary preclinical R&D programs and external partnerships in biopharma, with focus on metabolic and cardiovascular diseases – spanning small molecule drug discovery and bioprocessing of allogeneic cell therapies. Katrin heads teams for iPSC-differentiation, downstream validation of immune evasion edits and genetic QC. She oversees manufacturing process optimization focused on GMP-compatibility, scalability, ATMP regulatory compliance, and COGS, and collaboratively drives GMP-aligned gene editing process development. Katrin earned her PhD in Cellular Neuroscience from the Max-Planck-Institute for Experimental Medicine, Goettingen in 2011.

In 38 Days

You have registered for this webinar